Status:
COMPLETED
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
Lead Sponsor:
Andre Tsin Chih Chen
Conditions:
Recurrent Glioblastoma Multiforme
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. The treatment comprises maximal safe resection followed by radiotherapy and chemotherapy. Despite appropriate management...
Eligibility Criteria
Inclusion
- 18 years of age or older
- KPS equal or greater than 60
- Anatomopathological confirmation of GBM
- Previous RT with therapeutic doses
- At least 5 months from the end of RT course
- Not a candidate to surgical resection
- Patients with partial resection after resection of recurrent GBM will be allowed
- Patients with local progression after resection of recurrent GBM will be allowed
- Lesion with a maximal 150cc volume, as defined by enhancing portion in contrast enhanced MRI
- Hemoglobin levels (Hb) equal or greater than 10ng/dl. Blood transfusions to correct the Hb will be allowed.
Exclusion
- Important comorbidities
- Concomitant chemotherapy
- Contraindication to MRI
- Brainstem glioma
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01464177
Start Date
October 1 2011
End Date
August 1 2024
Last Update
December 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital das Clinicas da Faculdade de Medicina da USP
São Paulo, São Paulo, Brazil, 05403-010